We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics UK Ltd.

Download Mobile App




Elekta to Acquire Impac Medical Systems

By HospiMedica staff writers
Posted on 01 Feb 2005
Print article
Elekta AB (Stockholm, Sweden) has agreed to acquire Impac Medical Systems, Inc. (Mountain View, CA, USA), a provider of information systems for managing radiation and medical oncology and related clinical practices. The acquisition will enable Elekta, a supplier of advanced clinical systems for high precision radiation treatment of cancer and for non- or minimally invasive treatment of brain disorders, to offer customers a new, broad range of healthcare information products for clinical, administrative, outcome and decision-support purposes

Elekta will pay U.S.$24 in cash for each share of Impac common stock outstanding, which represents a premium of 22% over the Impac closing price on January 14, 2005, and is equal to a diluted equity value of about $250 million, and an enterprise value of about $190 million.

By joining forces, Elekta and Impac will be able to provide a unique, fully-integrated system that addresses the total spectrum of the cancer care process from diagnosis through treatment planning, treatment delivery, and follow-up, including decision support and cancer registry. Also, the companies' complementary geography presence will allow for more rapid deployment of Impac's systems into Europe and Asia/Pacific, while providing Impac's U.S. customers with greater choice and improved radiation therapy systems. Elekta's customers will be able to improve treatment efficiency through access to the full array of Impac's cancer management systems.

"The acquisition of Impac is an important step in the strategic development of Elekta and our ongoing efforts to improve cancer care, " remarked Dr. Laurent Leksell, president and CEO of Elekta. "The addition of Impac's strong management and software engineering team creates a significant new dimension to our solutions for cancer treatment.






Related Links:
Elekta
Impac Medical Systems
Gold Member
Real-Time Diagnostics Onscreen Viewer
GEMweb Live
Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
New
Examination Light
Avante Vista Flex
New
Bioengineered Collagen Implant
Tapestry Biointegrative Implant

Print article

Channels

Patient Care

view channel
Image: The portable biosensor platform uses printed electrochemical sensors for the rapid, selective detection of Staphylococcus aureus (Photo courtesy of AIMPLAS)

Portable Biosensor Platform to Reduce Hospital-Acquired Infections

Approximately 4 million patients in the European Union acquire healthcare-associated infections (HAIs) or nosocomial infections each year, with around 37,000 deaths directly resulting from these infections,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.